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ABSTRACT
Objective: The present study deals with the development, validation, and application of simple, precise, and accurate high-performance liquid 
chromatography (HPLC) method for the simultaneous estimation of metformin hydrochloride and ertugliflozin in pharmaceutical formulation and 
to validate.
Methods: The analytical conditions were optimized on BDS C8 column (150 mm × 4.6 mm, 5 µm) at room temperature. The mobile phase consists 
of buffer: acetonitrile in 55:45 v/v ratio. Injection volume was 10 µl. The flow rate was maintained at 1.0 ml/min, and the analysis was carried out at 
224 nm.
Results: The method was found to be linear in the concentration range of 125–750 µg/ml and 1.875–11.25 µg/ml for metformin hydrochloride and 
ertugliflozin with regression coefficient r2 = 0.999. The method was found to be precise with percentage relative standard deviation below 2%. The 
limit of detection and limit of quantification were found to be within the limits. The percentage recovery of the developed method was 100.15%. All 
the validation parameters such as robustness, recovery, and precision were found to be within the limits. Degradation parameters such as acid, base, 
thermal and peroxide, light, temperature, and humidity were performed and found that the drugs are stable in all the extreme conditions.
Conclusions: A simple, accurate, precise, and less time-consuming reversed-phase HPLC method for the simultaneous estimation of metformin 
hydrochloride and ertugliflozin has been developed and validated in accordance with the ICH guidelines.
Keywords: Metformin hydrochloride, Ertugliflozin, Reversed-phase - high-performance liquid chromatography, Validation, Simultaneous, Degradation.
INTRODUCTION
Type 2 diabetes is a disease in which the body does not make enough 
insulin to control the level of glucose in the blood or when the body is 
unable to use insulin effectively. The result is a high level of glucose in 
the blood. The two active substances such as metformin hydrochloride 
and ertugliflozin work in different ways to lower glucose levels. 
Metformin hydrochloride is an antihyperglycemic agent (AHA) that 
improves glucose tolerance in patients with type 2 diabetes mellitus 
by lowering both basal and post-prandial plasma glucose. It is not 
chemically or pharmacologically related to any other class of oral AHA. 
Metformin decreases hepatic glucose production, decreases intestinal 
absorption of glucose, and improves insulin sensitivity by increasing 
peripheral glucose uptake, and utilization ertugliflozin helps to lower 
blood glucose by making the patient pass out glucose in the urine. It 
does this by blocking a protein in the kidneys (called sodium-glucose 
cotransporter-2 [SGLT2]) that normally take glucose back into the 
blood from the kidneys [1,2].
Metformin hydrochloride is chemically called as N, N-dimethylimido-
dicarbonimidic diamide hydrochloride (Fig. 1) and does not related 
to any other classes of oral antihyperglycemic agents. It is a white 
to off-white crystalline compound with a molecular formula of 
C4H11N5•HCl [3].
Ertugliflozin is the fourth SGLT2 inhibitor approved by the FDA. The 
chemical name of ertugliflozin L-pyroglutamic acid is (1S,2S,3S,4R,5S)-5-(4-
chloro-3-(4-ethoxy benzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo 
octane-2,3,4-triol, compound with (2S)-5oxopyrrolidine- 2-carboxylic 
acid (Fig. 2), and its molecular formula is C8H15NO2 [4,5].
Even though numerous methods are available for the estimation of 
metformin hydrochloride individually and in combination with other 
drugs, no method has been reported for the estimation of metformin 
hydrochloride and ertugliflozin simultaneously [6-16].
METHODS
The reference sample of metformin hydrochloride and ertugliflozin 
was obtained as a gift samples, and the tablet containing metformin 
hydrochloride 500 mg and ertugliflozin 7.5 mg was procured from the local 
market. Water (high-performance liquid chromatography [HPLC] grade) 
from Rankem; acetonitrile (HPLC grade), orthophosphoric acid (AR grade), 
sodium hydroxide (pure), and hydrogen peroxide (pure) from Merck Ltd., 
and 0.45 µm Nylon filter was from Zodiac life sciences were used.
Instrumentation
Waters HPLC 2695 system equipped with quaternary pumps, photodiode 
array detector, and autosampler integrated with Empower 2 Software. 
UV-VIS spectrophotometer, PG Instruments T60 with special bandwidth 
of 2 mm and 10 mm, and matched quartz cells integrated with UV 
win 6 software were used for measuring absorbances of metformin 
hydrochloride and ertugliflozin solutions, Electronic Balance, Denver pH 
meter, Ultrasonicator - BVK Enterprises India.
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Chromatographic conditions
Optimized chromatographic conditions for the separation were used 
as Standard BDS C8 (150 mm × 4.6 mm, 5 mm particle size) column. 
Temperature was maintained ambient, mobile phase used was 
buffer: acetonitrile (55:45 v/v), and the flow rate was maintained at 1 ml/
min. The diluent used throughout the method was water: acetonitrile 
(50:50 v/v) and the runtime was 6 min. All the samples and mobile phase 
were degassed for 30 min and filtered by ultrasonic filtration using 0.45-
µm nylon (N66) 47-mm membrane filter. Detection was carried out at 
224 nm using PDA detector with an injection volume of 10 µl. Using the 
above-optimized conditions, method was developed.
Preparation of buffer
Buffer: (0.01%KH2PO4)
About 1.36 g of potassium dihydrogen phosphate was weighed and 
transferred into a 1000 ml volumetric flask added about 100 ml of 
milli-Q water and finally made the volume up to 1000 ml with milli-Q 
water.
Orthophosphoric acid buffer
1 ml of orthophosphoric acid was diluted to 1000 ml with HPLC grade 
water.
Preparation of mobile phase
Buffer (55%) and acetonitrile (45%) were mixed and degassed in an 
ultrasonicate water bath for 10 min and then filtered through 0.45 µ 
filter under vacuum filtration.
Diluent
Diluent used throughout the method was water: acetonitrile (50:50 v/v) 
chosen purely based on the solubility of the drugs.
Preparation of standard solutions
Accurately weighed and transferred 500 mg of metformin hydrochloride 
and 7.5 mg of ertugliflozin working standards into a 100 ml clean dry 
volumetric flasks; 10 ml of diluent was added and sonicated for 10 min 
and made up to the final volume with diluent.
Preparation of sample solution
A total of 10 tablets were weighed, and their mean weight was determined 
and crushed in mortar. An amount of powder weight equivalent to 
500 mg of metformin hydrochloride and 7.5 mg of ertugliflozin was 
taken and transfered to 100 ml volumetric flask. The powder obtained 
was dissolved in mobile phase and sonicated for 20 min for complete 
extraction. The solution was made up to the volume with mobile phase. 
The solution was filtered through membrane filter. The stock solution 
was further diluted with diluent to get a concentration of 500 µg/ml of 














AT = Average area of each main peak obtained from chromatogram of 
the sample solution
AS = Average area of each main peak obtained from chromatograms of 
the standard solution
WS = Weight of each metformin hydrochloride and ertugliflozin in 
standard solution (mg/ml)
WT = Weight of each metformin hydrochloride and ertugliflozin in 
sample (mg/ml)
DS = Dilution of standard solution
DT =Dilution of test solution
P = Potency of each standard
Method validation [17,18]
System suitability
System suitability tests are a fundamental part of liquid chromatographic 
method. It ensures that system is working correctly. System suitability 
parameters such as number of theoretical plates, retention time, and 
tailing factor were evaluated. This was performed by injecting mixture 
of standard in six replicates.
Linearity
The linearity of the proposed method was determined by quantitative 
dilution of the standard solution of metformin hydrochloride and 
ertugliflozin to obtain a solution in concentration range of 125–
750 µg/ml and 1.875–11.25 µg/ml for metformin hydrochloride and 
ertugliflozin, respectively. A graph of peak area versus concentration 
in μg/ml was plotted for all three drugs in triplicate. The slope, intercept, 
and correlation coefficient of the regression line were determined.
Fig. 1: Typical chromatogram of metformin hydrochloride and ertugliflozin
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Limit of detection (LOD) and limit of quantitation (LOQ)
The LOD and LOQ represent the concentration of analyte that would 
yield signal-to-noise ratio of 3 for LOD and 10 for LOQ. LOD and LOQ 
were calculated using the following formula,
LOD = 3.3 σ/S
LOQ = 10 σ/S
Where σ = standard deviation of response (peak area) and S = average 
slope of the calibration curve.
Method precision
The method precision of the proposed method was determined by 
injecting six replicates of sample and standard on the same day to 
ensure that the analytical method is repeatable.
System precision
The system precision is checked by injecting six replicates of standard 
solution to ensure that the analytical system is working properly.
Accuracy
The accuracy of this method was performed at three different levels 
(50%, 100%, and 150%), by the addition of a known amount of standard 
to the sample at each level. Each level was repeated 3 times (n=3).
Robustness
Robustness is the measure of optimized method capacity to remain 
unaffected by small but deliberate variations in method parameters 
such as mobile phase flow rate (±0.2 ml/min), wavelength nm (±1 nm), 
and column oven temperature (±1°C).
Degradation studies [19]
Oxidative degradation
To 1 ml of stock solution of metformin hydrochloride and ertugliflozin, 
1 ml of 20% hydrogen peroxide (H2O2) was added separately. The 
solutions were kept for 30 min. For HPLC study, the resultant solution 
was diluted to obtain (500 µg/ml and 7.5 µg/ml) solution and 10 µl 
were injected into the system, and the chromatograms were recorded 
to assess the stability of sample.
Acid degradation
As described in the oxidative degradation, the same method was 
followed using 2N hydrochloric acid and refluxed for 30 min.
Alkali degradation
The same procedure was followed as the above, in which 1 ml of 2N 
sodium hydroxide was used and refluxed for 30 min.
Thermal degradation
The standard drug solution was placed in an oven at 105°C for 6 h to study 
dry heat degradation. For HPLC study, the resultant solution was diluted to 
500 µg/ml and 7.5 µg/ml of solution and 10 µl was injected into the system, 
and the chromatograms were recorded to assess the stability of the sample.
Photo stability
The photochemical stability of the drug was also studied by exposing 
the solution to UV light by keeping the beaker in UV Chamber for 7 days 
in photostability chamber. For HPLC study, the resultant solution was 
diluted to obtain 500 µg/ml and 7.5 µg/ml of solutions and 10 µl was 
injected into the system, and the chromatograms were recorded to 
assess the stability of sample.
Water degradation
Stress testing under neutral conditions was studied by refluxing the 
drug in water for 6 h at a temperature of 60°C. For HPLC study, the 
resultant solution was diluted to 500 µg/ml and 7.5 µg/ml of solution 
and 10 µL was injected into the system, and the chromatograms were 
recorded to assess the stability of the sample.
RESULTS
System suitability
The system suitability was performed by injecting mixed standard 
solution containing 500 µg/ml of metformin hydrochloride and 
7.5 µg/ml of ertugliflozin in six replicates. The acceptance criteria for 
evaluating system suitability are percentage relative standard deviation 
(% RSD) <2, tailing factor ˂ 2, resolution >2, and theoretical plate ˃ 2000. 
Table 1: Results of system suitability studies
Replicates (n=6) Metformin hydrochloride Ertugliflozin Resolution
RT (min) USP plate count USP tailing RT (min) USP plate count USP tailing
1 2.334 5356 1.34 3.136 7732 1.25 5.7
2 2.335 5640 1.33 3.138 7487 1.25 5.6
3 2.336 5406 1.32 3.142 7428 1.24 5.7
4 2.336 5544 1.34 3.142 7225 1.27 5.7
5 2.336 5241 1.36 3.142 6981 1.25 5.7
6 2.338 5359 1.32 3.143 6985 1.26 5.7
Fig. 3: Graphs representing calibration curve of (a) metformin HCl and (b) ertugliflozin
a b
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The result indicates that the system suitability parameters are within 
the acceptable limits, hence ideal for the chromatographic samples. The 
results are summarized in Table 1.
Linearity
Linearity of the proposed method was determined by constructing 
calibration graph between the tested concentration level and 
corresponding peak areas for metformin hydrochloride and ertugliflozin 
in triplicate. The results showed an excellent correlation between peak 
areas and concentrations level within the tested concentration range 
of 125–750 µg/ml for metformin hydrochloride and 1.875–11.25 µg/
ml for ertugliflozin. The correlation coefficients were >0.999 for all 
two drugs, which meet the method validation acceptance criteria, and 
hence, the method is said to be linear for the drugs [Fig. 3a and b].
LOD and LOQ
The LOD and LOQ were found to be 1.70 µg/ml and 5.16 µg/ml 
for metformin hydrochloride and 0.07 µg/ml and 0.21 µg/ml for 
ertugliflozin which indicates that the method is sensitive. The results 
are summarized in Table 2.
Method precision
The %RSD value for six replicates injection of sample and standard 
carried out on the same day was found to be <2%, which indicates that 
the method is repeatable. The results for method precision are given 
in Table 3.
System precision
System precision was determined by measuring the peak area of six 
replicate injections of standard solution. The value of %RSD was found 
to be <2, which ensures that the analytical system is working properly. 
The results of system precision are tabulated in Table 3.
Accuracy
The accuracy of this method was determined by calculating percent 
recovery of metformin hydrochloride and ertugliflozin in formulation 
at three different levels (50%, 100%, and 150%). The percentage 
recovery obtained was found to be in the range of 99.13–101.63% for 
metformin hydrochloride and 99.05–101.10% for ertugliflozin. The 
accepted limits of mean recovery are 98–102% and the obtained results 
were within the acceptable range, which indicates that recovery values 
were good, affirming the accuracy of the developed method. The results 
are summarized in Tables 4 and 5.
Robustness
The method was found to be robust when minor changes were made 
in optimized chromatographic conditions such as oven temperature 
(±5°C), mobile phase flow rate (±0.1 ml/min), and ratio of mobile 
phase (±5 ml). It was observed that there was no marked change in 
the analytical data of the drugs which indicate good reliability during 
normal usage. The results are shown in Table 6.
Force degradation studies
Force degradation of metformin hydrochloride and ertugliflozin under 
the conditions of hydrolysis acidic, basic, oxidation, photolysis, thermal, 
and humidity was carried out.
In acidic conditions (2N hydrochloride for 3 h), it was found that 5.97% 
of metformin hydrochloride and 5.37% of ertugliflozin content were 
degraded, respectively.
In basic condition (2N sodium hydroxide for 3 h), it was found that 
4.66% of metformin hydrochloride and 4.19% of ertugliflozin content 
were degraded, respectively.
The drug sample when subjected to oxidation (20% of hydrogen 
peroxide), it was found that 3.64% of metformin hydrochloride and 
3.86% of ertugliflozin content were degraded, respectively.
In thermal condition (at 105°C for 6 h), it was found that 3.81% of 
metformin hydrochloride and 2.63% of ertugliflozin content were 
degraded, respectively.
Table 2: LOD and LOQ results
Drug LOD LOQ
Metformin HCl (mg/ml) 1.70 5.16
Ertugliflozin (mg/ml) 0.07 0.21
LOD: Limit of detection LOQ: Limit of quantitation
Table 4: Accuracy data for metformin hydrochloride
% Level Amount spiked (µg/ml) Amount recovered (µg/ml) % Recovery Mean %recovery
50% 250 253.73 101.49 100.15%
250 254.06 101.63
250 252.96 101.18
100% 500 498.89 99.78
500 495.99 99.20
500 495.67 99.13
150% 750 747.76 99.70
750 746.09 99.48
750 748.11 99.75
Table 3: Precision data of metformin and ertugliflozin
Replicates (n=6) Intraday Interday
Area of metformin HCl Area of ertugliflozin Area of metformin HCl Area of ertugliflozin
1 8061896 345429 8083648 342481
2 8093162 346408 8025772 347098
3 8054073 343925 8045907 340545
4 8045184 343865 8066204 347348
5 8053730 344007 8095717 347348
6 8070321 345636 8022367 344224
Mean 8063061 344878 8056603 344841
S.D 17015.1 1087.4 30300.4 2900.7
%RSD 0.2 0.3 0.4 0.8
N: Number of injections, SD: Standard deviation, % RSD: Percentage relative standard deviation
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The drug sample when exposed to UV light for 7 days, it was found that 
2.87% of metformin hydrochloride and 2.09% of ertugliflozin content 
were degraded, respectively.
The drug sample when placed under neutral conditions (refluxing the 
drug in water for 6 h at temperature 60°C), it was found that 1.23% 
of metformin hydrochloride and 1.11% of ertugliflozin content were 
degraded, respectively.
No interference was observed due to excipients and other components 
that are present in the pharmaceutical dosage form and as well in the 
degraded products, so it can be concluded that the developed method 
is stability indicating reversed-phase HPLC (RP-HPLC) method for 
simultaneous estimation of metformin hydrochloride and ertugliflozin 
in the formulation combination. The results for forced degradation 
studies are shown in Table 7.
CONCLUSIONS
No method is available for the estimation of metformin hydrochloride 
and ertugliflozin combination, so a new simple, precise, accurate, and 
repeatable RP-HPLC method for the estimation of these simultaneously 
have been developed and validated according to the ICH guidelines. 
All the validation parameters including system suitability, linearity, 
accuracy, precision, LOD, LOQ, and robustness were within the 
recommended limits of the ICH. The developed method has a total run 
time of 6 min, which permits the analysis of a large number of samples 
in a short period of time, thereby reducing solvent cost. Exposure of 
the drugs to different stress conditions such as acid, base, UV, thermal, 
photolytic, and water showed the drugs are stable in all the conditions. 
Developed method can be used for route analysis of these compounds 
simultaneously.
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